Drug Overview
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen. By promoting tubulin assembly into microtubules while simultaneously preventing disassembly, Jevtana inhibits mitotic and interphase cellular functions, non-specifically inhibiting cell replication.
Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen. By promoting tubulin assembly into microtubules while simultaneously preventing disassembly, Jevtana inhibits mitotic and interphase cellular functions, non-specifically inhibiting cell replication.
Table of Contents
Product ProfilesJevtana: Prostate cancer
List of Figures
Figure 1: Jevtana for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Jevtana for prostate cancer
Figure 3: Drug assessment summary of Jevtana for prostate cancer
Figure 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Jevtana drug profile
Table 2: Jevtana pivotal Phase III data in prostate cancer
Table 3: Jevtana Phase III data in prostate cancer
Table 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
